Retrospective analysis shows pre-treatment scintigraphy predicts xerostomia risk in thyroid cancer patients, guiding interventions.
To evaluate whether pre-treatment salivary gland scintigraphy (SGS) with technetium-99m pertechnetate (99mTcO4-) can predict the risk of moderate to severe salivary gland dysfunction and xerostomia in differentiated thyroid cancer (DTC) patients following their first radioiodine-131 (131I) therapy. We retrospectively enrolled 149 DTC patients (107 females, 42 males; mean age 46.6±12.7 years) who underwent total thyroidectomy between October 2022 and March 2024. All subjects received pre-treatment SGS to measure the uptake index (UI) and excretion fraction (EF) of bilateral parotid and submandibular glands. Patients then underwent 131I therapy (1.85-5.55GBq) and repeat SGS 6-12 months later under identical conditions. Xerostomia severity was assessed using the xerostomia inventory (XI) score, categorizing patients into no/mild (XI 11-23) versus moderate-extreme xerostomia (XI 24-55). Post-therapy, all glands exhibited significant declines in UI (parotid and submandibular glands, P<0.001) and EF (P≤0.004). There was no significant correlation between administered 131I dose and percentage changes in UI (ΔUI%) or EF (ΔEF). However, higher 131I doses were associated with increased rates of moderate-severe xerostomia (P=0.015) and higher mean XI scores (P=0.008). Receiver operating characteristic (ROC) analysis demonstrated that pre-treatment UI reliably predicted moderate to severe functional decline (ΔUI% >20%) with areas under the curve (AUC) of 0.866 for the right parotid, 0.793 for the left parotid, 0.769 for the right submandibular, and 0.816 for the left submandibular glands (all P<0.001). Additionally, ΔUI% in both submandibular glands differed significantly between patients with no/mild and moderate-extreme xerostomia (right: P=0.004; left: P=0.012). Pre-treatment (99mTcO4-SGS uptake index is a dependable predictor of moderate to severe salivary gland dysfunction and xerostomia following 131I therapy in DTC patients, enabling early identification of individuals at high risk and guiding tailored preventive strategies.
No takes yet. Share an insight, caveat, or question.
Hui et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: